Tony Coles, Cerevel CEO

Cerev­el's stock rock­ets up on re­lease of ear­ly da­ta in schiz­o­phre­nia, fol­lowed by an of­fer­ing

A cou­ple of years ago, when Pfiz­er shut down its neu­ro­science di­vi­sion, Bain Cap­i­tal picked up the pieces and spun them out in­to a new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.